Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Preparation and Evaluation of ZD2 Peptide .

ACS omega

Han Z, Sergeeva O, Roelle S, Cheng H, Gao S, Li Y, Lee Z, Lu ZR.
PMID: 30729224
ACS Omega. 2019 Jan 31;4(1):1185-1190. doi: 10.1021/acsomega.8b02729. Epub 2019 Jan 14.

Positron emission tomography (PET) is a sensitive modality for cancer molecular imaging. We aim to develop a PET probe for sensitive detection and risk stratification of prostate cancer by targeting an abundant microenvironment oncoprotein, extradomain-B fibronectin (EDB-FN). The probe...

Cite
Han Z, Sergeeva O, Roelle S, et al. Preparation and Evaluation of ZD2 Peptide . ACS Omega. 2019;4(1):1185-1190doi: 10.1021/acsomega.8b02729.
Han, Z., Sergeeva, O., Roelle, S., Cheng, H., Gao, S., Li, Y., Lee, Z., & Lu, Z. R. (2019). Preparation and Evaluation of ZD2 Peptide . ACS omega, 4(1), 1185-1190. https://doi.org/10.1021/acsomega.8b02729
Han, Zheng, et al. "Preparation and Evaluation of ZD2 Peptide ." ACS omega vol. 4,1 (2019): 1185-1190. doi: https://doi.org/10.1021/acsomega.8b02729
Han Z, Sergeeva O, Roelle S, Cheng H, Gao S, Li Y, Lee Z, Lu ZR. Preparation and Evaluation of ZD2 Peptide . ACS Omega. 2019 Jan 31;4(1):1185-1190. doi: 10.1021/acsomega.8b02729. Epub 2019 Jan 14. PMID: 30729224; PMCID: PMC6356864.
Copy Download .nbib Format: NLM
Polydisulfide Based Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agents.

Israel journal of chemistry

Lu ZR, Wu X.
PMID: 21331318
Isr J Chem. 2010 Aug;50(2):220-232. doi: 10.1002/ijch.201000016.

Macromolecular Gd(III) complexes are advantageous over small molecular Gd(III) complexes in contrast enhanced magnetic resonance imaging (MRI) because of their prolonged blood circulation and preferential tumor accumulation. However, macromolecular contrast agents have not been approved for clinical applications because...

Cite
Lu ZR, Wu X. Polydisulfide Based Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agents. Isr J Chem. 2010;50(2):220-232doi: 10.1002/ijch.201000016.
Lu, Z. R., & Wu, X. (2010). Polydisulfide Based Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agents. Israel journal of chemistry, 50(2), 220-232. https://doi.org/10.1002/ijch.201000016
Lu, Zheng-Rong, and Wu, Xueming. "Polydisulfide Based Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agents." Israel journal of chemistry vol. 50,2 (2010): 220-232. doi: https://doi.org/10.1002/ijch.201000016
Lu ZR, Wu X. Polydisulfide Based Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agents. Isr J Chem. 2010 Aug;50(2):220-232. doi: 10.1002/ijch.201000016. PMID: 21331318; PMCID: PMC3038583.
Copy Download .nbib Format: NLM
Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.

American journal of nuclear medicine and molecular imaging

Wu X, Yu G, Lindner D, Brady-Kalnay SM, Zhang Q, Lu ZR.
PMID: 25250202
Am J Nucl Med Mol Imaging. 2014 Jul 15;4(6):525-36. eCollection 2014.

Non-invasive accurate detection of prostate cancer is critical for clinical management of the disease. Molecular MRI has a potential for accurate detection of prostate cancer with high spatial resolution. Fibronectin is a hallmark of epithelial-mesenchymal transition occurred in aggressive...

Cite
Wu X, Yu G, Lindner D, et al. Peptide targeted high-resolution molecular imaging of prostate cancer with MRI. Am J Nucl Med Mol Imaging. 2014;4(6):525-36
Wu, X., Yu, G., Lindner, D., Brady-Kalnay, S. M., Zhang, Q., & Lu, Z. R. (2014). Peptide targeted high-resolution molecular imaging of prostate cancer with MRI. American journal of nuclear medicine and molecular imaging, 4(6), 525-36.
Wu, Xueming, et al. "Peptide targeted high-resolution molecular imaging of prostate cancer with MRI." American journal of nuclear medicine and molecular imaging vol. 4,6 (2014): 525-36.
Wu X, Yu G, Lindner D, Brady-Kalnay SM, Zhang Q, Lu ZR. Peptide targeted high-resolution molecular imaging of prostate cancer with MRI. Am J Nucl Med Mol Imaging. 2014 Jul 15;4(6):525-36. eCollection 2014. PMID: 25250202; PMCID: PMC4171839.
Copy Download .nbib Format: NLM
Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate.

American journal of nuclear medicine and molecular imaging

Wu X, Balu N, Li W, Chen Y, Shi X, Kummitha CM, Yu X, Yuan C, Lu ZR.
PMID: 24116353
Am J Nucl Med Mol Imaging. 2013 Sep 19;3(5):446-55. eCollection 2013.

Molecular imaging of atherosclerotic biomarkers is critical for non-invasive detection and diagnosis of atherosclerotic plaques and therapeutic management. Fibrin and fibronectin accumulate at elevated levels in atherosclerotic plaques and are associated with atherogenesis and disease progression. Molecular imaging of...

Cite
Wu X, Balu N, Li W, et al. Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate. Am J Nucl Med Mol Imaging. 2013;3(5):446-55
Wu, X., Balu, N., Li, W., Chen, Y., Shi, X., Kummitha, C. M., Yu, X., Yuan, C., & Lu, Z. R. (2013). Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate. American journal of nuclear medicine and molecular imaging, 3(5), 446-55.
Wu, Xueming, et al. "Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate." American journal of nuclear medicine and molecular imaging vol. 3,5 (2013): 446-55.
Wu X, Balu N, Li W, Chen Y, Shi X, Kummitha CM, Yu X, Yuan C, Lu ZR. Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate. Am J Nucl Med Mol Imaging. 2013 Sep 19;3(5):446-55. eCollection 2013. PMID: 24116353; PMCID: PMC3784808.
Copy Download .nbib Format: NLM
Cryo-Imaging and Software Platform for Analysis of Molecular MR Imaging of Micrometastases.

International journal of biomedical imaging

Qutaish MQ, Zhou Z, Prabhu D, Liu Y, Busso MR, Izadnegahdar D, Gargesha M, Lu H, Lu ZR, Wilson DL.
PMID: 29805438
Int J Biomed Imaging. 2018 Apr 01;2018:9780349. doi: 10.1155/2018/9780349. eCollection 2018.

We created and evaluated a preclinical, multimodality imaging, and software platform to assess molecular imaging of small metastases. This included experimental methods (e.g., GFP-labeled tumor and high resolution multispectral cryo-imaging), nonrigid image registration, and interactive visualization of imaging agent...

Cite
Qutaish MQ, Zhou Z, Prabhu D, et al. Cryo-Imaging and Software Platform for Analysis of Molecular MR Imaging of Micrometastases. Int J Biomed Imaging. 2018;2018:9780349doi: 10.1155/2018/9780349.
Qutaish, M. Q., Zhou, Z., Prabhu, D., Liu, Y., Busso, M. R., Izadnegahdar, D., Gargesha, M., Lu, H., Lu, Z. R., & Wilson, D. L. (2018). Cryo-Imaging and Software Platform for Analysis of Molecular MR Imaging of Micrometastases. International journal of biomedical imaging, 20189780349. https://doi.org/10.1155/2018/9780349
Qutaish, Mohammed Q, et al. "Cryo-Imaging and Software Platform for Analysis of Molecular MR Imaging of Micrometastases." International journal of biomedical imaging vol. 2018 (2018): 9780349. doi: https://doi.org/10.1155/2018/9780349
Qutaish MQ, Zhou Z, Prabhu D, Liu Y, Busso MR, Izadnegahdar D, Gargesha M, Lu H, Lu ZR, Wilson DL. Cryo-Imaging and Software Platform for Analysis of Molecular MR Imaging of Micrometastases. Int J Biomed Imaging. 2018 Apr 01;2018:9780349. doi: 10.1155/2018/9780349. eCollection 2018. PMID: 29805438; PMCID: PMC5899875.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries